Restrictions lowered for cannabis-derived drug

DEA’s decision to reclassify Epidiolex does not change the status of non-FDA-approved CBD products that are already on the market. Those products, which include dietary supplements, cosmetics, and beverages, touting benefits like promoting relaxation and relieving anxiety and pain, will remain on Schedule I—drugs with no proven medical use and high potential for abuse.

... read more at: https://cen.acs.org/pharmaceuticals/rare-disease/Restrictions-lowered-cannabis-derived-drug/96/i40

by